Burger line Burger line Burger line
Logo Logo Logo
Burger line Burger line Burger line
Menu
Sign in
Sign in

NICE Endorses AstraZeneca’s Tagrisso for NSCLC Patients With Specific Mutation

The UK’s National Institute for Health and Care Excellence (NICE) has said the Cancer Drugs Fund, part of the National Health Service, should offer AstraZeneca’s Tagrisso (osimertinib) for patients with non-small cell lung cancer (NSCLC).

NICE recommended the drug for people with early-stage NSCLC who have had prior surgery to remove a tumor and who suffer from epidermal growth factor receptor (EGFR) genetic mutations.

Tagrisso blocks the mutated EGFR protein which causes cancer growth and may also help shrink tumor size.

December 6, 2021

https://www.fdanews.com/

0 items in Cart
Cart Subtotal:
Go to cart
You will be able to Pay Online or Request a Quote
Catalog
Services
Company

We use "cookies*  to ensure the functionality of our website, recognise your browser or device, learn more about your interests, and provide you with essential features and services and for additional purposes, including:

Recognising you when you sign-in to use our services. This allows us to provide you with product recommendations, display personalised content, and provide other customised features and services.
Keeping track of your specified preferences. You may set your preferences through Your Account..
Keeping track of items stored in your shopping basket and personal cabinet.
Conducting research and diagnostics to improve ChemDiv’s content, products, and services.
Delivering content, including ads, relevant to your interests on ChemDiv’s site
Reporting. This allows us to measure and analyse the performance of our services.

By  cookies you give consent to the processing of your personal data, including transfer to third parties. Further information can be found in our privacy policy.

Accept all cookies